"Well the AIFA's okay to a revolutionary therapy for heart failure, which reduces hospitalizations and mortality by up to 30%: these are glyphozines (SLGT2), born as anti-diabetic and which currently represent the most important therapeutic innovation of heart failure, capable of reducing mortality and hospitalizations even in non-diabetic patients ".
This was stated by the Italian Society of Cardiology (Sic).
"The reimbursement of Dapaglifozin, the first drug of the glyphzine class to be approved in Italy for the treatment of heart failure in patients with and without type 2 diabetes, represents excellent news for the more than one million Italians suffering from this serious pathology, for the scientific community and in particular for cardiologists - says Pasquale Perrone Filardi, president-elect of SIC - Until now to allow a protective effect on the heart thanks to the help of these innovative molecules, those who suffered from heart failure without diabetes had to pay for the drug and turn to the diabetologist rather than the cardiologist, with a waste of resources and time, increasing the complexity of the therapeutic path which is already difficult in itself because it must be tailored ".
"The extension of the prescribability of glyphzines also to the cardiologist will allow a more effective management of the patient with heart failure, with or without diabetes, the simplification of the care pathway and, above all, a 25-30% reduction in hospitalizations and mortality", continues Perrone Filardi. Heart failure (or heart failure) is the final outcome of all heart disease and essentially occurs when the heart is no longer able to pump enough blood. In Italy it affects about 2% of the general population and is increasing especially in the over 65s, with a mortality of 20% in its most serious forms. It absorbs 2% of the national health expenditure but 60% of these costs are dedicated to hospitalizations and only 10% to the cost of drugs. In the last two years,says Ciro indolfi, president of SIC, "we have had extraordinary results from large clinical studies on glyphzines that have shown great efficacy in reducing mortality and hospitalization for heart failure but also in improving the patient's quality of life".